REG - IXICO plc - Trading Update

IXICOAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251016:nRSP5655Da&default-theme=true

RNS Number : 5655D  IXICO plc  16 October 2025

IXICO plc

("IXICO", the "Company" or the "Group")

 

Trading update for the year ended 30 September 2025

Double digit revenue growth following increased strategic focus

 

 

16 October 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in
neuroscience imaging and biomarker analytics, using its AI-driven platform to
help advance drug development in neurological disorders, today announced a
trading update, pre-audit, for its financial year ended 30 September 2025
("FY25").

 

·     FY25 revenues exceed market expectations at £6.5 million (2024:
£5.8 million).  Year-on-year revenues increased by 13% reflecting new
contract wins, existing contract extensions and a broadening of market
offering into new verticals.

 

·     Year-end order book of £13.8 million (2024: £15.3 million).  In
H2, the order book increased from £13.1 million (31 March 2025) reflecting
£4.2 million of new contract wins and contract extensions offset by £3.3
million of revenues recognised and £0.2 million of minor project scope and
foreign exchange adjustments.

 

·     Acceleration of new wins is continuing into FY26 with £0.9 million
of new contracts and contract extensions signed since the end of September.

 

·     Year-end cash of £3.5 million (2024: £1.8 million).
Year-on-year increase reflects a £3.7 million (net of fees) capital raise
completed in H1-25 offset by investments made in the Company's I-L-S strategy.

 

·     Full year loss before interest, tax, depreciation, and amortisation
("EBITDA") is expected to be slightly improved on market expectations at no
more than a £1.6 million loss (2024: £1.7 million loss).  This reflects the
double-digit revenue growth offset by specific investments designed to sustain
this rate of growth in future years.

 

The Company intends to announce its audited results for FY25 in December 2025.

 

 

Bram Goorden, CEO of IXICO, commented: "I am thrilled with the performance of
the IXICO team this first full financial year of my tenure with the Company.
The oversubscribed capital raise at the start of the year allowed us to double
down investments in specific areas of growth targeting new customers and novel
verticals. It is my strong belief that these initial positive signals will
translate into a sustained period of growth and value creation as we further
scale our impact in the thriving market of neurodegenerative disease biopharma
R&D. Failure is not an option.  Patients are waiting for solutions, and
the biopharma industry is working harder than ever in CNS to develop
treatments."

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit)
Regulations 2019. Upon the publication of this announcement via the Regulatory
Information Service, this inside information is now considered to be in the
public domain.

Ends

 

For further information please contact:

 IXICO plc                                   +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited           +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFFFFWIEISELS



            Copyright 2019 Regulatory News Service, all rights reserved